Crizotinib is an ALK (anaplastic lymphoma kinase) mutation-targeting agent employed in the management of ALK-positive non-small cell pulmonary carcinoma (NSCLC) and various other neoplastic disorders. Here, ALK is linked to non-small cell lung carcinoma.